Table 1. Baseline Patient Characteristics*.
| Characteristics | SD48W, N = 94 | SD24W, N = 93 |
|---|---|---|
| Mean age (SD), y | 56 (12) | 56 (13) |
| Age >50 y | 64 (68) | 59 (63) |
| Male sex | 51 (54) | 52 (56) |
| Mean weight (SD), kg | 69 (13) | 69 (11) |
| Mean BMI (SD), kg/m2 | 26.7 (4.5) | 26.3 (3.5) |
| BMI (SD), kg/m2 | ||
| ≤27.0 | 54 (57.4) | 52 (55.9) |
| 27.1–30.0 | 21 (22.3) | 29 (31.2) |
| >30.0 | 19 (20.2) | 12 (12.9) |
| Mean hemoglobin level (SD), g/dL | 14.4 (1.5) | 14.7 (1.4) |
| Mean white cell count (SD), 109cells/L | 5.6 (1.4) | 5.8 (1.5) |
| Mean neutrophil count (SD), 109cells/L | 3.0 (1.1) | 3.2 (1.2) |
| Mean platelet count (SD), 109cells/L | 175 (61) | 182 (64) |
| Mean albumin level (SD), g/dL | 4.3 (0.4) | 4.3 (0.3) |
| Mean total bilirubin level (SD), mg/dL | 1.0 (0.4) | 1.0 (0.5) |
| Mean AST quotient (SD), ULN | 2.2 (1.2) | 2.3 (1.1) |
| Mean ALT quotient (SD), ULN | 3.4 (2.1) | 3.8 (2.3) |
| Mean APRI score (SD) | 1.5 (1.0) | 1.5 (1.1) |
| APRI score | ||
| ≤1.50 | 56 (59.6) | 50 (53.8) |
| 1.51–2.0 | 12 (12.7) | 21 (22.5) |
| >2.00 | 26 (27.7) | 22 (23.7) |
| Mean HCV RNA level (SD), log10 IU/mL | 6.0 (0.9) | 6.0 (0.6) |
| HCV RNA level, IU/mL | ||
| ≤800,000 | 33 (35) | 35 (38) |
| >800,000 | 61 (65) | 58 (62) |
| Subgenotype | ||
| 2a | 64 (68) | 66 (71) |
| 2b | 24 (26) | 20 (22) |
| 2a + 2b | 6 (6) | 7 (8) |
| IL-28B rs8099917 genotype† | ||
| TT | 65 (74) | 60 (71) |
| GT and GG | 23 (26) | 24 (29) |
SD: standard deviation, BMI: body mass index, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ULN: upper limit of normal, APRI: aspartate aminotransferase to platelet ratio index, HCV: hepatitis C virus, IU: international unit, IL: interleukin, SD48W: 48 weeks of peginterferon alfa-2a plus weight-based ribavirin, SD24W: 24 weeks of peginterferon alfa-2a plus weight-based ribavirin.
*Values are numbers (percentages) unless otherwise indicated.
†Available number of patients (%) for analysis: 88 (94%) and 84 (90%) in SD48W and SD24W arms, respectively.